Article Dans Une Revue Pharmacogenomics Année : 2015

Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab

Résumé

Aim: The efficacy of a cetuximab-based regimen used to treat metastatic colorectal cancer (mCRC) could be influenced by VEGFA polymorphisms. Materials & methods: We studied the effects of five polymorphisms in the VEGFA gene (-2549D/I, -1154G/A, -460T/C, +405G/C and +936C/T) on the outcome of 98 mCRC patients treated with FOLFIRI plus cetuximab. Results: Patients homozygous for the -2549D, -1154G and -460T alleles did exhibit higher response rates to treatment and longer progression-free survival compared with others. In addition, the DGTGC and IGCGC haplotypes were significantly associated with a lower risk of disease progression. Conclusion: These findings suggest that VEGFA genetic variations might influence response/resistance of FOLFIRI plus cetuximab treatment in mCRC patients.

Fichier principal
Vignette du fichier
rollin2015.pdf (190.82 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Licence

Dates et versions

hal-02381189 , version 1 (12-05-2022)

Licence

Identifiants

Citer

Jérôme Rollin, Audrey Payancé, Valérie Gouilleux-Gruart, Michelle Boisdron-Celle, Nicolas Azzopardi, et al.. Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab. Pharmacogenomics, 2015, 16 (18), pp.2035-2043. ⟨10.2217/pgs.15.139⟩. ⟨hal-02381189⟩
325 Consultations
326 Téléchargements

Altmetric

Partager

  • More